ICUI — ICU Medical, Inc. stock price, charts and financials

QT52ICU Medical, Inc.

ICU Medical, Inc. (NASDAQ: ICUI) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
152.65
-0.26-0.17%
ICUIQT52ICU Medical, Inc.·NASDAQ
152.65-0.17%
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E129.36EPS (ttm)1.18Insider Own18.76%Shs Outstand24.99MPerf Week-2.45%
Market Cap3.82BForward P/E15.79EPS next Y9.67Insider Trans-0.95%Shs Float24.50MPerf Month-18.48%
Enterprise Value4.79BPEG21.10EPS next Q2.13Inst Own-Short Float5.85%Perf Quarter8.75%
Income30.00MP/S1.77EPS this Y640.68%Inst Trans-Short Ratio4.80Perf Half Y20.55%
Sales2.16BP/B1.77EPS next Y10.61%ROA0.76%Short Interest1.43MPerf YTD7.00%
Book/sh86.10P/C12.80EPS next 5Y6.13%ROE1.41%52W High192.86 -20.85%Perf Year18.24%
Cash/sh11.92P/FCF25.59EPS past 3/5Y- -62.60%ROIC-21.74%52W Low112.50 35.69%Perf 3Y21.58%
Dividend Est.-EV/EBITDA16.07Sales past 3/5Y-0.74% 11.90%Gross Margin37.56%Volatility2.04% 2.63%Perf 5Y-37.45%
Dividend TTM-EV/Sales2.22EPS Y/Y TTM124.43%Oper. Margin5.04%ATR (14)4.68Perf 10Y21.91%
Dividend Ex-Date-Quick Ratio1.21Sales Y/Y TTM-9.36%Profit Margin1.39%RSI (14)27.23Recom2.00
Dividend Gr. 3/5Y-Current Ratio2.43EPS Q/Q12.86%SMA20-8.46%Beta0.86Target Price186.40
Payout0.00%Debt/Eq0.66Sales Q/Q0.55%SMA50-9.15%Rel Volume1.30Prev Close152.91
Employees13,000LT Debt/Eq0.64EarningsNov 05SMA2004.40%Avg Volume293.36KPrice152.65
IPO DateMar 31, 1992Option/ShortYes / YesEPS/Sales Surpr.23.85% 2.71%Net Debt/EBITDA3.27Volume381,263Change-0.17%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedRaymond JamesStrong Buy$97$200
Aug-07-26ReiteratedNeedhamBuy$165$187
Aug-07-26ReiteratedBTIGBuy$170$200
Jul-21-26ReiteratedKeybancOverweight$164$182
Jun-15-26InitiatedBTIGBuy$170
May-27-26UpgradeNeedhamHoldBuy$165
Apr-27-26ReiteratedKeybancOverweight$180$164
Apr-17-26ReiteratedPiper SandlerOverweight$178$163
Feb-20-26ReiteratedPiper SandlerOverweight$153$178
Feb-20-26ReiteratedKeybancOverweight$173$180
Latest News· Times ET
Sep-17-26
Sep-16-26
Sep-15-26
Sep-14-26
Sep-07-26
Aug-27-26
Aug-25-26
Aug-23-26
Aug-14-26
Aug-13-26
Aug-08-26
Aug-07-26
Aug-06-26
Company

ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,1592,2302,382
Cost of Goods Sold Incl. D&A1,3481,4101,557
Gross Profit811820825
Selling, General and Administrative Excl. Other616625639
Research and Development868789
Other Operating Expense0154
Operating Income10910743
Interest Expense84105107
Unusual Expense
Non-Operating Income (Expense)-302-2
Net Income Before Taxes-43-66
Income Taxes-32252
Consolidated Net Income301-118
Net Income From Continuing Operations271-118
Net Income301-118
EPS (Recurring)1.200.03-4.83
EPS (Basic, Before Extraordinaries)1.200.03-4.83
EPS (Diluted)1.180.03-4.83
EBITDA29832743
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio129.364,852.72
Price To Sales Ratio1.771.601.56
Gross Margin37.5636.7734.63
Operating Margin5.054.801.81
Net Margin1.390.04-4.95
Shares Outstanding252524
Market Capitalization3,8163,5673,724
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$199.13$173.41$147.68$121.95$96.23 Close Price0.00M1.17M2.35M3.52M4.69MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Sanzone Virginia RuthVP, General CounselSep 03 '26Sale168.694,856819,15014,604Sep 03
Bonnell Brian MichaelChief Financial OfficerSep 01 '26Sale175.006,3811,116,67556,062Sep 01
Bonnell Brian MichaelChief Financial OfficerAug 31 '26Sale172.799,3071,608,14462,443Aug 31
Woolson DanielVP, GM-Infusion CapitalAug 13 '26Sale181.335,417982,26517,062Aug 13
Sousa BenChief Information OfficerAug 12 '26Sale178.322,250401,2093,076Aug 12
Voigtlander Christian B.Chief Operating OfficerAug 11 '26Sale182.938,9291,633,40437,377Aug 11
FINNEY ELISHA WDirectorAug 11 '26Sale182.4837868,9784,871Aug 11
Woolson DanielPresidentMay 22 '26Sale132.212,123280,68522,479May 22
Sanzone Virginia RuthVP, General CounselMay 14 '26Sale124.082,447303,62419,460May 15
KENNEDY KOLLEEN TDirectorMay 13 '26Option Exercise0.001,25404,539May 13
Hernandez LaurieDirectorMay 13 '26Option Exercise0.001,25404,862May 13
FINNEY ELISHA WDirectorMay 13 '26Option Exercise0.001,25405,249May 13
Abbey DonaldDirectorMay 13 '26Option Exercise0.001,25406,004May 13
Hoffmeister David FDirectorMay 13 '26Option Exercise0.001,25406,004May 13
Greenberg David C.DirectorMay 13 '26Option Exercise0.001,25409,214May 13
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.